The researchers fused the H2 antibody fragment with a CD3 antibody fragment to establish BsAbs that could augment the activation of T cells to enhance the recognition and destruction of cancer cells expressing p53 R175H peptide–HLA complex. The gene discussed is TP53; the disease is cancer.